AG-7404
Based on 1 Customer Validation
AG-7404 is an orally active, irreversible inhibitor of the picornavirus 3C protease. AG-7404 blocks the processing of viral polyproteins, thereby inhibiting viral replication. AG-7404 has synergistic antiviral activity with capsid inhibitors such as V-073 (HY-104074) or BTA798 (HY-106254) and is effective against V-073-resistant variants. AG-7404 is used in the study of enterovirus infections such as poliovirus.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 98.45%
- CAS No.: 343565-99-1
- 화학식: C26H29N5O7
- 분자량:523.54
-
보관:
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- Protocol
- 순도&문서
- References
-
Help & FAQs
Biological Activity
제품 설명
In Vitro
AG-7404 (0.080-0.674 μM; 3 d) inhibits viral replication in HeLa cells with poliovirus with an EC50 of 0.080-0.674 μM[1].
AG-7404 (0.218-0.819 μM; 3 d) remains active in V-073-resistant poliovirus strains with an EC50 of 0.218-0.819 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HeLa cells (for wild-type and vaccine-derived poliovirus strains)
-
Concentration:0.080-0.674 μM
-
Incubation Time:3 days
-
Result:Dose-dependently reduced viral cytopathic effect (CPE) as assessed by crystal violet staining and CTG assay.
EC50 values were determined for each strain, demonstrating broad activity against wild-type, circulating vaccine-derived (cVDPV), and immunodeficient vaccine-derived (iVDPV) strains.
Chemical Information
-
CAS No. 343565-99-1
-
Appearance Solid
-
분자량 523.54
-
화학식 C26H29N5O7
-
Color White to off-white
-
SMILES
O=C(NCC1)[C@@H]1C[C@@H](/C=C/C(OCC)=O)NC([C@@H](N2C(C(NC(C3=NOC(C)=C3)=O)=CC=C2)=O)CC#C)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
용액&용해도
In Vitro:
DMSO : 25 mg/mL (47.75 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocol
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
순도&문서
-
Data Sheet (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Rhoden E, et al. Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds. Antiviral Res. 2013 May;98(2):186-91. [Content Brief]
[2]. Ravlo E, et al. Synergistic combination of orally available safe-in-man pleconaril, AG7404, and mindeudesivir inhibits enterovirus infections in human cell and organoid cultures. Cell Mol Life Sci. 2025 Jan 23;82(1):57. [Content Brief]
[3]. Rhoden E,et al. Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds. Antiviral Res. 2013 May;98(2):186-91. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9101 mL | 9.5504 mL | 19.1007 mL | 47.7518 mL |
| 5 mM | 0.3820 mL | 1.9101 mL | 3.8201 mL | 9.5504 mL | |
| 10 mM | 0.1910 mL | 0.9550 mL | 1.9101 mL | 4.7752 mL | |
| 15 mM | 0.1273 mL | 0.6367 mL | 1.2734 mL | 3.1835 mL | |
| 20 mM | 0.0955 mL | 0.4775 mL | 0.9550 mL | 2.3876 mL | |
| 25 mM | 0.0764 mL | 0.3820 mL | 0.7640 mL | 1.9101 mL | |
| 30 mM | 0.0637 mL | 0.3183 mL | 0.6367 mL | 1.5917 mL | |
| 40 mM | 0.0478 mL | 0.2388 mL | 0.4775 mL | 1.1938 mL |
AG-7404 Related Classifications
HY-19476 Related Classifications
Powered by Bioz